insuficiência mitral

Highlights TCT 2019

TCT 2019 | COAPT at 3 Years: MitraClip Reached Functional Mitral Regurgitation Target

Courtesy of SBHCI. Prognosis of patients with cardiac failure who develop secondary mitral regurgitation due to dilation is uncertain.&nbsp;&nbsp; The COAPT study was carried out in 78 centers across the US and Canada and included patients with moderate to severe mitral regurgitation (3 or 4 crossovers) symptomatic despite optimal medical treatment (OMT).&nbsp; 614 patients were<a href="https://solaci.org/en/2019/10/01/tct-2019-coapt-3-year-outcomes-from-a-randomized-trial-of-the-mitraclip-in-patients-with-heart-failure-and-severe-secondary-mitral-regurgitation/" title="Read more" >...</a>

EuroPCR 2019 | COAPT: la reducción de la insuficiencia mitral está asociada a menos hospitalizaciones y muerte

EuroPCR 2019 | COAPT: Mitral Valve Reduction is Associated to Lower Hospitalization and Death

This new analysis shows the mechanism behind the benefit of using MitraClip and the necessary degree of residual mitral regurgitation (MR) to have an impact. Regardless the intervention type, patients with cardiac failure and secondary mitral regurgitation present lower hospitalization for cardiac failure, all-cause mortality and improved quality of life the lower the MR. MitraClip<a href="https://solaci.org/en/2019/05/23/europcr-2019-coapt-mitral-valve-reduction-is-associated-to-lower-hospitalization-and-death/" title="Read more" >...</a>

TAVI en bajo riesgo con “cero” mortalidad y “cero” stroke

The Significance of Aetiology on Mitral Regurgitation

Courtesy of Dr. Carlos Fava. The aetiology of mitral regurgitation (MR) may be divided into primary, organic or degenerative MR, and secondary or functional MR. These two present different physiopathology. The treatment strategy is different for each, and edge-to-edge treatment with Mitraclip is currently emerging as a valid alternative for high-risk patients. This study analyzed 943 patients<a href="https://solaci.org/en/2019/05/08/the-significance-of-aetiology-on-mitral-regurgitation/" title="Read more" >...</a>

Mitral Valve Repair with MirtaClip Was Feasible and Safe

Transcatheter mitral valve repair (TMVR) with MitraClip was shown feasible and safe, and therefore a viable option for symptomatic patients with severe mitral valve regurgitation of prohibitive risk. In this regard, the procedure alleviates symptoms, cardiac regurgitation and has a potential benefit on ventricular remodeling. However, many patients presented atrial fibrillation (AF) and mitral valve<a href="https://solaci.org/en/2019/04/10/mitral-valve-repair-with-mirtaclip-was-feasible-and-safe/" title="Read more" >...</a>

TCT 2018 | COAPT: MitraClip en pacientes con insuficiencia mitral secundaria

TCT 2018 | COAPT: MitraClip in Patients with Secondary Mitral Regurgitation

The prognosis of patients with heart failure and mitral regurgitation secondary to ventricular dysfunction and dilation is guarded. Percutaneous mitral valve treatment of these patients may at least improve their symptoms. This study was conducted in 78 sites in the United States and Canada, and included patients with moderate-to-severe (3+) or severe (4+) mitral regurgitation who<a href="https://solaci.org/en/2018/10/08/tct-2018-coapt-mitraclip-in-patients-with-secondary-mitral-regurgitation/" title="Read more" >...</a>

TCT 2018 | REDUCE-FMR: Anuloplastia indirecta en insuficiencia mitral secundaria

TCT 2018 | REDUCE-FMR: Indirect Annuloplasty in Secondary Mitral Regurgitation

Prior studies such as the AMADEUS, TITAN or TITAN II have shown reduction of mitral valve regurgitation (MR) with the Carillon device. This sham-controlled randomized study tested the efficacy of this device in secondary mitral regurgitation. Primary end point was echocardiographic MR reduction (blind core lab) and secondary end point were hospitalization for cardiac failure,<a href="https://solaci.org/en/2018/10/08/tct-2018-reduce-fmr-indirect-annuloplasty-in-secondary-mitral-regurgitation/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Mitral Valve Repair in Patients with Cardiac Failure

The mitral valve is a complex apparatus dependent on left atrium and left ventricle functionality. Dilation of these cavities might affect mitral annulus morphology and lead to valve dysfunction, generating mitral regurgitation (MR). This type of MR has been called functional, since leaflets and tendinous chordae do not present lesions themselves; instead, they malfunction ‘secondary’<a href="https://solaci.org/en/2018/10/01/mitral-valve-repair-in-patients-with-cardiac-failure/" title="Read more" >...</a>

MITRA-FR: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Courtesy of Dr. Adolfo Ferrero. INTRODUCCION: In patients with chronic heart failure and reduced left ventricular ejection fraction, severe secondary mitral valve regurgitation is associated with bad prognosis. Whether percutaneous mitral valve repair improves clinical results in this patient population, remains unclear, despite prior multicenter studies supporting this view. METHODS: Patients with severe secondary mitral<a href="https://solaci.org/en/2018/09/07/mitra-fr-percutaneous-repair-or-medical-treatment-for-secondary-mitral-regurgitation/" title="Read more" >...</a>

MITRA FR: el testeo del MitraClip en las insuficiencias mitrales funcionales

ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation

Courtesy of Dr. Carlos Fava. In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ventricular geometry and function.  At present, prognosis is based on ventricular function and the regular course of action is optimal medical treatment. Even though some studies have shown edge-to-edge percutaneous repair<a href="https://solaci.org/en/2018/08/30/esc-2018-mitra-fr-testing-mitraclip-for-secondary-mitral-regurgitation/" title="Read more" >...</a>

Treating Tricuspid and Mitral Valves with MitraClip Improves Quality of Life

Courtesy of Dr. Carlos Fava. It has been shown that significant tricuspid regurgitation (TR) is an independent predictor of bad evolution in the presence of  mitral valve disease. Its prevalence is not low, reaching up to 50% in patients undergoing surgery for mitral regurgitation (MR). This study included 61 patients with significant TR and MR. 27<a href="https://solaci.org/en/2018/07/02/treating-tricuspid-and-mitral-valves-with-mitraclip-improves-quality-of-life/" title="Read more" >...</a>

Top